- Prevalence of specific histopathological patterns and their subtypes (N=158).
| Pathological patterns | n (%) |
|---|---|
| Cholestatic/bile duct disorders (n=92) | |
| Extrahepatic biliary atresia | 32 (34.8) |
| Paucity of bile ducts (syndromic and non-syndromic) | 20 (21.7) |
| Neonatal hepatitis | 10 (10.9) |
| PFIC-1 | 3 (3.3) |
| PFIC-2 | 12 (13.0) |
| PFIC-3 | 5 (5.4) |
| Choledochal cyst | 1 (1.1) |
| PSC | 3 (3.3) |
| Cholestasis, NOS | 6 (6.5) |
| Inflammatory/infectious disorders (n=21) | |
| Autoimmune hepatitis | 4 (19.0) |
| Abscess | 3 (14.3) |
| Infectious (HCV, fungal) | 3 (14.3) |
| Cholestatic hepatitis | 1 (4.8) |
| CAH, NOS | 10 (47.6) |
| Metabolic disorders (n=19) | |
| Glycogen storage disorders | 6 (31.6) |
| NAFLD | 6 (31.6) |
| Cystic fibrosis | 2 (10.5) |
| Lysosomal storage diseases | 1 (5.3) |
| A1ATD | 1 (5.3) |
| Metabolic disorders, NOS | 3 (15.8) |
| Neoplastic disorders (n=12) | |
| Benign | 5 (41.7) |
| Malignant, 1ry | 3 (25.0) |
| Malignant, 2ry | 4 (33.3) |
Values are presented as numbers and percentages (%).
PFIC: progressive familial intrahepatic cholestasis,
PSC: primary sclerosing cholangitis, NOS: not otherwise specified,
HCV: hepatitis C virus, CAH: chronic active hepatitis,
NAFLD: non-alcoholic fatty liver disease, A1ATD: alpha-1 antitrypsin deficiency